G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> WHO Members Delve Into Draft 5-Year Work Programme, Question Finance, Focus 22/11/2017 Catherine Saez World Health Organization member states’ first reactions to the secretariat-proposed draft work programme for the next five years were mixed this morning. Although many praised the effort and the vision of the programme of work, in particular its alignment with the United Nations Sustainable Development Goals, a number of countries found the programme ambitious without the needed financial backing, and sometimes straying from the core function of the organisation. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> Global Fund For AIDS, TB & Malaria Narrows Director Candidates To Four 23/10/2017 William New The Global Fund for AIDS, Tuberculosis and Malaria announced today it has narrowed the search to four high-level candidates, coming from backgrounds in banking, development agencies and United Nations programs. Continue reading -> World Health Summit: Failing Business Models In AMR And Vaccination 19/10/2017 Monika Ermert BERLIN -- With antimicrobial resistance (AMR) on the rise worldwide there is no time to lose for developing new antibiotic drugs, experts said during one of the last panels of this year’s World Health Summit in Berlin Tuesday. As in several other rounds during the three-day event, industry representatives underlined that there is an issue with the business model due to high risk and low return of investment for research in this area. Continue reading -> WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> WHO Members Delve Into Draft 5-Year Work Programme, Question Finance, Focus 22/11/2017 Catherine Saez World Health Organization member states’ first reactions to the secretariat-proposed draft work programme for the next five years were mixed this morning. Although many praised the effort and the vision of the programme of work, in particular its alignment with the United Nations Sustainable Development Goals, a number of countries found the programme ambitious without the needed financial backing, and sometimes straying from the core function of the organisation. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> Global Fund For AIDS, TB & Malaria Narrows Director Candidates To Four 23/10/2017 William New The Global Fund for AIDS, Tuberculosis and Malaria announced today it has narrowed the search to four high-level candidates, coming from backgrounds in banking, development agencies and United Nations programs. Continue reading -> World Health Summit: Failing Business Models In AMR And Vaccination 19/10/2017 Monika Ermert BERLIN -- With antimicrobial resistance (AMR) on the rise worldwide there is no time to lose for developing new antibiotic drugs, experts said during one of the last panels of this year’s World Health Summit in Berlin Tuesday. As in several other rounds during the three-day event, industry representatives underlined that there is an issue with the business model due to high risk and low return of investment for research in this area. Continue reading -> WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Members Delve Into Draft 5-Year Work Programme, Question Finance, Focus 22/11/2017 Catherine Saez World Health Organization member states’ first reactions to the secretariat-proposed draft work programme for the next five years were mixed this morning. Although many praised the effort and the vision of the programme of work, in particular its alignment with the United Nations Sustainable Development Goals, a number of countries found the programme ambitious without the needed financial backing, and sometimes straying from the core function of the organisation. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> Global Fund For AIDS, TB & Malaria Narrows Director Candidates To Four 23/10/2017 William New The Global Fund for AIDS, Tuberculosis and Malaria announced today it has narrowed the search to four high-level candidates, coming from backgrounds in banking, development agencies and United Nations programs. Continue reading -> World Health Summit: Failing Business Models In AMR And Vaccination 19/10/2017 Monika Ermert BERLIN -- With antimicrobial resistance (AMR) on the rise worldwide there is no time to lose for developing new antibiotic drugs, experts said during one of the last panels of this year’s World Health Summit in Berlin Tuesday. As in several other rounds during the three-day event, industry representatives underlined that there is an issue with the business model due to high risk and low return of investment for research in this area. Continue reading -> WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> Global Fund For AIDS, TB & Malaria Narrows Director Candidates To Four 23/10/2017 William New The Global Fund for AIDS, Tuberculosis and Malaria announced today it has narrowed the search to four high-level candidates, coming from backgrounds in banking, development agencies and United Nations programs. Continue reading -> World Health Summit: Failing Business Models In AMR And Vaccination 19/10/2017 Monika Ermert BERLIN -- With antimicrobial resistance (AMR) on the rise worldwide there is no time to lose for developing new antibiotic drugs, experts said during one of the last panels of this year’s World Health Summit in Berlin Tuesday. As in several other rounds during the three-day event, industry representatives underlined that there is an issue with the business model due to high risk and low return of investment for research in this area. Continue reading -> WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> Global Fund For AIDS, TB & Malaria Narrows Director Candidates To Four 23/10/2017 William New The Global Fund for AIDS, Tuberculosis and Malaria announced today it has narrowed the search to four high-level candidates, coming from backgrounds in banking, development agencies and United Nations programs. Continue reading -> World Health Summit: Failing Business Models In AMR And Vaccination 19/10/2017 Monika Ermert BERLIN -- With antimicrobial resistance (AMR) on the rise worldwide there is no time to lose for developing new antibiotic drugs, experts said during one of the last panels of this year’s World Health Summit in Berlin Tuesday. As in several other rounds during the three-day event, industry representatives underlined that there is an issue with the business model due to high risk and low return of investment for research in this area. Continue reading -> WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Fund For AIDS, TB & Malaria Narrows Director Candidates To Four 23/10/2017 William New The Global Fund for AIDS, Tuberculosis and Malaria announced today it has narrowed the search to four high-level candidates, coming from backgrounds in banking, development agencies and United Nations programs. Continue reading -> World Health Summit: Failing Business Models In AMR And Vaccination 19/10/2017 Monika Ermert BERLIN -- With antimicrobial resistance (AMR) on the rise worldwide there is no time to lose for developing new antibiotic drugs, experts said during one of the last panels of this year’s World Health Summit in Berlin Tuesday. As in several other rounds during the three-day event, industry representatives underlined that there is an issue with the business model due to high risk and low return of investment for research in this area. Continue reading -> WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
World Health Summit: Failing Business Models In AMR And Vaccination 19/10/2017 Monika Ermert BERLIN -- With antimicrobial resistance (AMR) on the rise worldwide there is no time to lose for developing new antibiotic drugs, experts said during one of the last panels of this year’s World Health Summit in Berlin Tuesday. As in several other rounds during the three-day event, industry representatives underlined that there is an issue with the business model due to high risk and low return of investment for research in this area. Continue reading -> WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy